Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Elena Elimova

Best of ASCO® Toronto Conference 2025: Canadian Achievements in Cancer Research – Dr. Elena Elimova

4-year follow-up of a phase 2 trial.
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
Best of ASCO® Toronto Conference 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Co-Chairs

Dr. Aly-Khan Lalani

Dr. Natasha Leighl

Icon Chair Speaker

Speakers

Dr. Elena Elimova

Studies / Trials Discussed

4-year follow-up of a phase 2 trial.
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)

Studies/trials discussed:

4-year follow-up of a phase 2 trial. Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
Tagged